Lapatinib/Pazopanib

拉帕替尼/培唑帕尼

Report date: 2026/04/29 17:38:05

Base Information

Drug NameLapatinib/Pazopanib
Drug Alias NamePazopanib/Lapatinib拉帕替尼+培唑帕尼Pazopanib+Lapatinib培唑帕尼+拉帕替尼培唑帕尼/拉帕替尼 +[6] 
ClassificationSmall molecules
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsEpidermal growth factor receptor erbB1 antagonists +[14] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[14] 
Therapy Area/IndicationsUterine Cervical NeoplasmsBreast NeoplasmsCarcinoma, Renal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsYes Pazopanib HydrochlorideLapatinib Ditosylate Hydrate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsBreast NeoplasmsCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A